A review of dose-limiting events in phase I trials: Antimetabolites show unpredictable relationships between dose and toxicity

Cancer Chemotherapy and Pharmacology

Volumn 47, Issue 1, 2001, Pages 2-10

  Seymour, L ^a   Eisenhauer, E ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Antimetabolites; Dose limiting toxicity; Endpoints; Phase I studies

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; AMETANTRONE; AMONAFIDE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; ASULACRINE ISETHIONATE; BREQUINAR; CAPECITABINE; CARBOPLATIN; CARZELESIN; CHLOROZOTOCIN; CYTOTOXIC AGENT; DICHLOROMETHOTREXATE; DOXIFLURIDINE; EDATREXATE; ESORUBICIN; FAZARABINE; GEMCITABINE; LOMETREXOL; MIVOBULIN ISETHIONATE; NOLATREXED; PEMETREXED; PIRITREXIM; PLEVITREXED; RALTITREXED; SEBRIPLATIN; TIAZOFURIN; TRIMETREXATE; TROXACITABINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CLINICAL TRIAL; DATA BASE; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG RESEARCH; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; RETROSPECTIVE STUDIES;

EID: 0034920261     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000228     Document Type: Article

References (116)

1. Workshop on phase I study design
2. Pharmacologically guided phase I clinical trials based upon preclinical drug development
3. Phase I trial design: Are new methodologies being put into practice?
4. Model guided determination of maximum tolerated dose in phase I clinical trials: Evidence for increased precision
5. Choice of starting Jose and escalation for phase I studies of antitumor agents
6. Design and results of phase I cancer clinical trials: 3 years experience at M.D. Anderson Cancer Centre
7. Accelerated titration designs for phase I clinical trials in oncology
8. New phase I trial methodology
9. Pharmacokinetics of brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study
10. Phase I clinical trials of intravenous 2′-deoxy-2′-(fluoromethylene) cytidine (FMdC) in patients with advanced solid tumors
11. Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule
12. Phase I pharmacokinetic and pharmacodynamic study of the new anthrapyrazole, CI-937 (DUP937)
13. Phase I study of ethylenediamine platinum (II) malonate (NSC 146 068), a second generation platinum analogue
14. A phase I study of meta-azidopyrimethamine ethanesulphonate (MZPES) - A new dihydrofolate reductase inhibitor
15. Phase I and clinical pharmacology trial of crisnatol (BWA770U) mesylate) using a monthly single-dose schedule
16. Phase I clinical study with pharmacokinetic analysis of 2-β-D-rubofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion
17. Phase I trial of spiromustine (NSC 172112) and evaluation of toxicity and schedule in murine model
18. Phase I clinical and pharmacokinetic trial of penclomedine using a novel, two-stage trial design for patients with advanced malignancy
19. Phase I clinical study of didemnin B
20. Phase I study of mafosfamide-cyclohexylamine (ASTA-Z-7557, NSC 345 842) and limited phase I data on mafosfamide-lysine
21. 3-Deazaguanine: Report of a phase I trial and drug-related cardiac toxicity
22. Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue
23. Modulation of antimetabolite effects: Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor CB 3717
24. Is body composition an important variable in the pharmacokinetics of anticancer drugs? A review and suggestions for further research
25. Body surface area as a basis for dosing of anticancer agents: Science, myth or habit?
26. Practical treatment guide for dose individualization in cancer chemotherapy
27. Pharmacogenetics in cancer etiology and chemotherapy
28. Pharmacogenetics and cancer chemotherapy
29. Population pharmacokinetic analysis of LY231514
30. LY231514 (MTA): Relationship of vitamin metabolite profile to toxicity
31. Plasma 2′-deoxyuridine as a surrogate marker of thymidylate synthase inhibition in patients treated with ZD9331
32. Trimetrexate: Predictors of severe or life threatening toxic effects
33. Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer
34. Phase I clinical study with 5′-deoxy-5-fluorouridine, a new fluoropyrimidine derivative
35. Phase I and pharmacokinetic study of brequinar sodium (NSC 368390)
36. Phase I clinical and pharmacokinetic trial of brequinar sodium (DUP 785; NSC 368390)
37. A phase I clinical and pharmacokinetic study of brequinar sodium DUP 785 (NSC 368390), using a weekly and a biweekly schedule
38. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer
39. 10-propargyl-5,8-dideazafolic acid, CB3717
40. 10-propargyl-5,8-dideazafolic acid, CB 3717
41. Clinical and pharmacologic reappraisal of dichloromethotrexate
42. Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (Fazarabine, NSC 281272)
43. A phase I clinical, plasma and cellular pharmacology study of gemcitabine
44. Phase I study of gemcitabine using a once every 2 weeks schedule
45. A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer
46. Phase I study of (6R)-5-10-dideazatetrahydrofolate: A folate antimetabolite inhibitory to de novo purine synthesis
47. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231541, using the modified continual reassessment method for dose escalation
48. A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate
49. Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors
50. Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days
51. A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U)
52. Phase I trial of ZD 1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors
53. Phase I evaluation and pharmacokinetics of tiazofurin (2-β-D-rubofuranosylthiazole-4-carboxamide NSC 286193)
54. Phase I clinical and pharmacokinetic study of trimetrexate using a daily ×5 schedule
55. A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion
56. Phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-infusion schedule
57. Phase I studies of trimetrexate using single and weekly dose schedules
58. A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: Clinical pharmacology and pharmacodynamics
59. Determination of the variables affecting clearance of the novel thymidylate synthase inhibitor ZD9331
60. Phase I study of ZD 9331 on a 5-day short infusion schedule given every 3 weeks
61. Phase I trial of ZD9331 in adult patients with refractory solid malignancies administered by 30-minute infusion on days 1 and 8 with the cycle repeated every 3 weeks
62. Phase I pharmacologic study of 9-amino-camptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks
63. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin
64. Phase I and clinical pharmacological evaluation of 4′-deoxydoxorubicin in patients with advanced cancer
65. A phase I trial of ametantrone acetate (NSC-287513)
66. Phase I clinical investigation of benzisoquinolinedione
67. Phase I clinical investigation of amonafide
68. Phase I study of carboplatin in patients with advanced cancer, intermittent intravenous bolus, and 24-hour infusion
69. Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion
70. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days
71. Phase I study of carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule
72. Phase I trial of the amsacrine analogue 9-({2-methoxy-r-[methylsulfonyl)amino]-phenyl}amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921)
73. 1) platinum in patients with metastatic solid tumours
74. Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent
75. Phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors
76. Phase I evaluation of chlorozotocin (NSC-178248): Weekly schedule
77. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks
78. Phase I trial of 5-day continuous infusion aziridinylbenzoquinone (AZQ, Diazaquone, NSC 182968)
79. Phase I and pharmacologic study of DMP 840 as a single infusion every three weeks
80. A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion
81. Phase I trial of Taxotere: Five-day schedule
82. Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion
83. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis
84. Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion
85. Phase I pharmacokinetic study of DUP-937, a new anthrapyrazole
86. Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks
87. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion
88. Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily ×5 intravenous administration
89. Phase I study of weekly-administered iproplatin [cis-dichloro-trans-dihydroxy-bis-isopropylamine platin (CHIP, JM9)]
90. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days
91. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer
92. Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer
93. Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies
94. Phase I trial of menogaril administered as an intermittent daily infusion for 5 days
95. A phase I study of menogaril in patients with advanced cancer
96. Phase I clinical trial of mitozolomide
97. Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days
98. Phase I study of N-Methylformamide in patients with advanced cancer
99. Phase I trial of N-methylformamide (NMF, NSC 3051)
100. Phase I study of oxaliplatin in patients with advanced cancer
101. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole
102. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents - Drug-polymer conjugates
103. Phase I and pharmacokinetic study of rhizoxin
104. Phase I clinical trial of the new taxoid RPR 109881A in a day 1 and 8 intravenous schedule every 3 weeks
105. Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule
106. Phase I study of TCNU, a novel nitrosourea
107. A phase I clinical evaluation of 1-(2-chloroethyl)-3-[2-(dimethylaminosulphonyl) ethyl]-1-nitrosourea (TCNU)
108. A clinical and pharmacokinetic phase I study of 1,2,4-triglycidylurazol (TGU, NSC 332488)
109. Phase I study of triglycidylurazol given on a 5-day IV schedule
110. Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors
111. Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer
112. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor
113. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors
114. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumours, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor
115. Phase I and pharmacokinetic study of intravenous vinzolidine